Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.
Marmé F, Krieghoff-Henning EI, Kiehl L, Wies C, Hauke J, Hahnen E, Harter P, Schouten PC, Brodkorb T, Kayali M, Heitz F, Zamagni C, González-Martin A, Treilleux I, Kommoss S, Prieske K, Gaiser T, Fröhling S, Ray-Coquard I, Pujade-Lauraine E, Brinker TJ. Marmé F, et al. Among authors: heitz f. Eur J Cancer. 2024 Dec 26;216:115199. doi: 10.1016/j.ejca.2024.115199. Online ahead of print. Eur J Cancer. 2024. PMID: 39742559 Free article.
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?
Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA. Kime A, et al. Among authors: heitz f. Arch Pathol Lab Med. 2024 Dec 9. doi: 10.5858/arpa.2024-0081-OA. Online ahead of print. Arch Pathol Lab Med. 2024. PMID: 39648143 Free article.
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Graybill WS, Vergote I, Pothuri B, Anttila M, O'Malley DM, Lorusso D, Haggerty AF, Fabbro M, Chan JK, Heitz F, Willmott LJ, Bruchim I, Zhuo Y, Estévez-García P, Monk BJ, Denys H, Knudsen A, Tinker AV, Sánchez LM, Provencher D, Barretina-Ginesta MP, Hartman J, Booth DV, González-Martín A. Graybill WS, et al. Among authors: heitz f. J Comp Eff Res. 2025 Jan;14(1):e240133. doi: 10.57264/cer-2024-0133. Epub 2024 Dec 6. J Comp Eff Res. 2025. PMID: 39641537 Free PMC article.
Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier.
Jamieson A, Grube M, Kommoss F, Lum A, Leung S, Chiu D, Henderson G, Heitz F, Heublein S, Zeimet AG, Hasenburg A, Diebold J, Walter C, Staebler A, Reynolds J, Lapuk A, McConechy MK, Huntsman DG, Gilks B, Kommoss S, McAlpine JN. Jamieson A, et al. Among authors: heitz f. Int J Gynecol Cancer. 2024 Dec 2;34(12):1888-1897. doi: 10.1136/ijgc-2024-005916. Int J Gynecol Cancer. 2024. PMID: 39461743
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators.
Denschlag D, Heitz F, Pfisterer J, Tutschkow D, Reuss A, Meier W, Harter P, Wimberger P, Mirza MR, Ray-Coquard I, Scambia G, Kim JW, Colombo N, Oaknin A, Sehouli J, Lindemann K, Lebreton C, Eichbaum M, Spiegelberg S, Woopen H, du Bois A. Denschlag D, et al. Among authors: heitz f. Int J Gynecol Cancer. 2024 Dec 2;34(12):1914-1923. doi: 10.1136/ijgc-2024-005663. Int J Gynecol Cancer. 2024. PMID: 39322609
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F. González-Martín A, et al. Among authors: heitz f. J Clin Oncol. 2024 Dec 20;42(36):4294-4304. doi: 10.1200/JCO.24.00668. Epub 2024 Sep 18. J Clin Oncol. 2024. PMID: 39292975 Clinical Trial.
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A. Monk BJ, et al. Among authors: heitz f. Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284381 Free article. Clinical Trial.
Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
Fricová L, Kommoss S, Scambia G, Ferron G, Kocián R, Harter P, Anchora LP, Bats AS, Novàk Z, Walter CB, Raspagliesi F, Lambaudie E, Bahrehmand K, Andress J, Klát J, Pasternak J, Matylevich O, Szeterlak N, Minář L, Heitz F, Căpîlna ME, Runnebaum I, Cibula D, Sláma J. Fricová L, et al. Among authors: heitz f. Gynecol Oncol. 2024 Nov;190:179-185. doi: 10.1016/j.ygyno.2024.08.020. Epub 2024 Aug 28. Gynecol Oncol. 2024. PMID: 39197417
481 results